NDAORALCAPSULE
Approved
May 1971
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
RIMACTANE (rifampin) by Oxford Drug Design is clinical pharmacology oral administration rifampin is readily absorbed from the gastrointestinal tract. Approved for asymptomatic carriers of neisseria meningitidis to eliminate meningococci from the nasopharynx, meningococcal infection because of the possibility of the rapid emergence of resistant organisms (see ), the treatment of all forms of tuberculosis. First approved in 1971.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RIMACTANE (rifampin) is an oral small-molecule antibiotic that inhibits DNA-dependent RNA polymerase activity in Mycobacterium tuberculosis, making it bactericidal against slow and intermittently growing TB organisms. It is indicated for treatment of all forms of tuberculosis and elimination of Neisseria meningitidis from asymptomatic carriers. Rifampin is rapidly absorbed, widely distributed including to the CNS, and undergoes hepatic metabolism with enterohepatic circulation.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30%), signaling potential team restructuring and transition to generic defense strategies.
Mechanism of Action
CLINICAL PHARMACOLOGY Oral Administration Rifampin is readily absorbed from the gastrointestinal tract. Peak serum concentrations in healthy adults and pediatric populations vary widely from individual to individual. Following a single 600 mg oral dose of rifampin in healthy adults, the peak serum…
Worked on RIMACTANE at Oxford Drug Design? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.